S&P 500   4,331.68 (-0.42%)
DOW   34,154.79 (-0.04%)
QQQ   344.95 (+0.11%)
AAPL   160.94 (+0.78%)
MSFT   302.14 (+1.83%)
FB   298.03 (+1.15%)
GOOGL   2,609.91 (+0.98%)
AMZN   2,830.42 (+1.91%)
TSLA   864.37 (-7.79%)
NVDA   222.14 (-2.45%)
BABA   112.45 (-0.81%)
NIO   21.56 (-4.85%)
AMD   104.89 (-5.26%)
CGC   6.96 (-3.73%)
MU   80.08 (-2.31%)
GE   88.95 (-0.41%)
T   24.00 (-1.03%)
F   19.74 (-0.85%)
DIS   135.42 (+1.36%)
AMC   14.77 (-7.34%)
PFE   53.66 (+1.23%)
ACB   3.86 (-4.93%)
BA   191.49 (-1.43%)
S&P 500   4,331.68 (-0.42%)
DOW   34,154.79 (-0.04%)
QQQ   344.95 (+0.11%)
AAPL   160.94 (+0.78%)
MSFT   302.14 (+1.83%)
FB   298.03 (+1.15%)
GOOGL   2,609.91 (+0.98%)
AMZN   2,830.42 (+1.91%)
TSLA   864.37 (-7.79%)
NVDA   222.14 (-2.45%)
BABA   112.45 (-0.81%)
NIO   21.56 (-4.85%)
AMD   104.89 (-5.26%)
CGC   6.96 (-3.73%)
MU   80.08 (-2.31%)
GE   88.95 (-0.41%)
T   24.00 (-1.03%)
F   19.74 (-0.85%)
DIS   135.42 (+1.36%)
AMC   14.77 (-7.34%)
PFE   53.66 (+1.23%)
ACB   3.86 (-4.93%)
BA   191.49 (-1.43%)
S&P 500   4,331.68 (-0.42%)
DOW   34,154.79 (-0.04%)
QQQ   344.95 (+0.11%)
AAPL   160.94 (+0.78%)
MSFT   302.14 (+1.83%)
FB   298.03 (+1.15%)
GOOGL   2,609.91 (+0.98%)
AMZN   2,830.42 (+1.91%)
TSLA   864.37 (-7.79%)
NVDA   222.14 (-2.45%)
BABA   112.45 (-0.81%)
NIO   21.56 (-4.85%)
AMD   104.89 (-5.26%)
CGC   6.96 (-3.73%)
MU   80.08 (-2.31%)
GE   88.95 (-0.41%)
T   24.00 (-1.03%)
F   19.74 (-0.85%)
DIS   135.42 (+1.36%)
AMC   14.77 (-7.34%)
PFE   53.66 (+1.23%)
ACB   3.86 (-4.93%)
BA   191.49 (-1.43%)
S&P 500   4,331.68 (-0.42%)
DOW   34,154.79 (-0.04%)
QQQ   344.95 (+0.11%)
AAPL   160.94 (+0.78%)
MSFT   302.14 (+1.83%)
FB   298.03 (+1.15%)
GOOGL   2,609.91 (+0.98%)
AMZN   2,830.42 (+1.91%)
TSLA   864.37 (-7.79%)
NVDA   222.14 (-2.45%)
BABA   112.45 (-0.81%)
NIO   21.56 (-4.85%)
AMD   104.89 (-5.26%)
CGC   6.96 (-3.73%)
MU   80.08 (-2.31%)
GE   88.95 (-0.41%)
T   24.00 (-1.03%)
F   19.74 (-0.85%)
DIS   135.42 (+1.36%)
AMC   14.77 (-7.34%)
PFE   53.66 (+1.23%)
ACB   3.86 (-4.93%)
BA   191.49 (-1.43%)
NASDAQ:IOBT

IO Biotech News Headlines

$7.22
+0.14 (+1.98%)
(As of 01/27/2022 12:22 PM ET)
Add
Compare
Today's Range
$6.95
▼
$7.79
50-Day Range
$6.38
▼
$10.90
52-Week Range
$5.82
▼
$17.88
Volume
1,768 shs
Average Volume
27,010 shs
Market Capitalization
$208.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
Get IO Biotech News Delivered to You Automatically

Sign up to receive the latest news and ratings for IOBT and its competitors with MarketBeat's FREE daily newsletter.

Media Mentions By Week

IO Biotech Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

IOBT
News Sentiment
▼
0.34

0.31
▲
Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

IOBT Articles
This Week
▼
2

1
▲
IOBT Articles
Average Week



IO Biotech (NASDAQ:IOBT) News Headlines Today

SourceHeadline
MarketBeat logoIO Biotech (NASDAQ:IOBT) Shares Down 7%
americanbankingnews.com - January 22 at 2:00 AM
finance.yahoo.com logoIO Biotech Announces Publication of Phase 1/2 Melanoma Clinical Trial Results in Nature Medicine
finance.yahoo.com - December 9 at 1:28 PM
finance.yahoo.com logoIO Biotech Announces Third Clinical Collaboration with Merck to Evaluate IO102-IO103 in Combination With KEYTRUDA® (pembrolizumab) as First-Line Treatment in a Phase 2 Multi-Arm Basket Trial
finance.yahoo.com - December 6 at 8:41 AM
nasdaq.com logoIO Biotech Trading 21% Higher
nasdaq.com - December 3 at 3:00 PM
realmoney.thestreet.com logoIO Biotech, Inc. (IOBT)
realmoney.thestreet.com - December 2 at 11:55 PM
Get IO Biotech News Delivered to You Automatically

Sign up to receive the latest news and ratings for IOBT and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 1/27/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.